Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7)

Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7)

This project receives funding from the European Union’s Seventh Framework Program (FP7/2007-2013) under grant agreement no 259939.

None

EuroTARGET is a European collaborative project on "Targeted therapy in Renal cell cancer: Genetic and Tumour related biomarkers for response and toxicity". It is funded by the European Commission under the Seventh Framework Programme (FP7). The project brings together 14 partner organisations (12 research institutes and 2 companies) from 8 European countries (www.eurotargetproject.eu).

Since a few years, specific drugs are available for patients with metastasized renal cell cancers that can suppress the development of new blood vessels in the tumor. However, not all patients show clinical benefit from therapy. In addition to this, toxicity is experienced by a substantial number of patients. And such toxicity frequently necessitates a reduction of the dose or even cessation of therapy. In individual patients, it is impossible to accurately predict response and toxicity. That means that many patients will be treated with the drugs while they will experience only side effects without any benefits. On the other hand, other patients may be treated with a suboptimal type of drug or dose.

The EuroTARGET project aims to collect specific information that will help to quickly predict the outcome of an individual’s treatment. This will allow physicians to effectively optimize a treatment regimen to target a patient’s individual condition. The specific information the EuroTARGET researchers are looking for are so-called biomarkers. A biomarker is a term often used to refer to a protein measured in blood whose concentration reflects the presence or severity of a disease.

In order to take inter-individual variability of drug and biomarker concentrations into account, a phase IV pharmacokinetic/pharmacodynamic (PK/PD) sub-study (EuT-PK/PD, Workpackage 7) focussing on sunitinib is being conducted in 10 German centers. Recently, this study was extended to pazopanib. Overall 1100 patients will be recruited in Europe, 100 will additionally participate in the PK/PD sub-study. The final goal of this work is to develop predictive PK/PD models for sunitinib and pazopanib which may assist the treating physician to individualize drug therapy.

In the proposed research, pharmacokinetic data from previous clinical trials will be used as a basis for the development of predictive PK/PD models for pazopanib.

[{ "PostingID": 84, "Title": "GSK-VEG10004", "Description": "Medicine: pazopanib, Condition: Carcinoma, Renal Cell, Phase: 1, GSK Clinical Study ID: VEG10004, Sponsor: GSK." },{ "PostingID": 92, "Title": "GSK-VEG111485", "Description": "Medicine: pazopanib, Condition: Carcinoma, Renal Cell, Phase: 1, GSK Clinical Study ID: VEG111485, Sponsor: GSK." },{ "PostingID": 1644, "Title": "VIIV-ESS40001", "Description": "A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/ZIAGEN/Zerit (3TC/ABC/d4T) Versus EPIVIR/ZIAGEN/Sustiva (3TC/ABC/EFV) Versus EPIVIR/ZIAGEN/GW433908/Norvir (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who are Antiretroviral Thera ...

Medicine: fosamprenavir, Condition: Infection, Human Immunodeficiency Virus I, Phase: 2, Clinical Study ID: ESS40001, Sponsor: ViiV" }]

The publication citation will be added after the research is published.